HLA-A and neoplasm: With TCR-based immunotherapy targeting tumor-associated antigens and metastatic drivers of EwS, such as CHM1 [22,33], STEAP1 [24], PAPPA [42], and PRAME [43], our group previously achieved efficacious in vitro and in vivo cytotoxic targeting of HLA-A*02:01+ EwS.